| Literature DB >> 33028635 |
Mysore S Veena1, Santanu Raychaudhuri2, Saroj K Basak3, Natarajan Venkatesan1, Parameet Kumar4, Roopa Biswas4, Rita Chakrabarti1, Jing Lu5, Trent Su6, Marcus Gallagher-Jones7, Marco Morselli5, Haiqing Fu8, Matteo Pellegrini5, Theodore Goldstein9, Mirit I Aladjem8, Matthew B Rettig10, Sharon P Wilczynski11, Daniel Sanghoon Shin10, Eri S Srivatsan12.
Abstract
We have observed overexpression of PACS-1, a cytosolic sorting protein in primary cervical tumors. Absence of exonic mutations and overexpression at the RNA level suggested a transcriptional and/or posttranscriptional regulation. University of California Santa Cruz genome browser analysis of PACS-1 micro RNAs (miR), revealed two 8-base target sequences at the 3' terminus for hsa-miR-34a and hsa-miR-449a. Quantitative RT-PCR and Northern blotting studies showed reduced or loss of expression of the two microRNAs in cervical cancer cell lines and primary tumors, indicating dysregulation of these two microRNAs in cervical cancer. Loss of PACS-1 with siRNA or exogenous expression of hsa-miR-34a or hsa-miR-449a in HeLa and SiHa cervical cancer cell lines resulted in DNA damage response, S-phase cell cycle arrest, and reduction in cell growth. Furthermore, the siRNA studies showed that loss of PACS-1 expression was accompanied by increased nuclear γH2AX expression, Lys382-p53 acetylation, and genomic instability. PACS-1 re-expression through LNA-hsa-anti-miR-34a or -449a or through PACS-1 cDNA transfection led to the reversal of DNA damage response and restoration of cell growth. Release of cells post 24-h serum starvation showed PACS-1 nuclear localization at G1-S phase of the cell cycle. Our results therefore indicate that the loss of hsa-miR-34a and hsa-miR-449a expression in cervical cancer leads to overexpression of PACS-1 and suppression of DNA damage response, resulting in the development of chemo-resistant tumors. Published in the U.S.A.Entities:
Keywords: DNA damage response; PACS-1; cancer biology; cervical cancer; genome stability; hsa-miR-449a; hsa-miRNA-34a; nuclear translocation; nuclear transport; oncogene; p53 acetylation; trafficking protein; tumor; tumor suppressor gene
Mesh:
Substances:
Year: 2020 PMID: 33028635 PMCID: PMC7863911 DOI: 10.1074/jbc.RA120.014048
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157